The regenerative surgical treatment of intra-bony peri-implantitis defects with Endobon® (test) versus an established bovine derived bone mineral (control) – a pilot study

Academic Center for Dentistry Amsterdam0 个研究点目标入组 25 人开始时间: 2020年2月20日最近更新: 2020年9月28日

试验速览

2020 results in https://doi.org/10.1111/clr.13651 (added 11/09/2020)

•1. During surgical exploration an intra-bony component of at least 3 mm at the deepest point must be present.
•2. The defect should have a minimum of 3 osseous walls (a circumference of the osseous defect of at least 270 degrees). Only 3 and 4 wall intraosseous defects will be included
•3. The defect must not be wider than 4 mm and the defect angle must be less than 35 degrees from axis of implant
•Note: If the same patient has more than one defect meeting the inclusion criteria only one such defect will be included in the study and the other defects will be treated with standard open flap debridement

•1. Diabetes mellitus (HbAlc = 6.5%)
•2. Taking corticosteroids or other anti-inflammatory prescription drug
•3. Taking medications known to induce gingival hyperplasia
•4. Allergic to penicillin or metronidazole
•5. History of taking systemic antibiotics in the preceding month
•6. Pregnant or lactating
•7. Stability of the Endobon® granules or control granules cannot be accomplished in the defect
•8. Failure of obtaining soft tissue closure
•9. Mobile implants

发起方

Academic Center for Dentistry Amsterdam